Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Buy" by Analysts

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) have been given an average recommendation of "Buy" by the ten analysts that are covering the firm, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $27.89.

Several research analysts have recently weighed in on CNTA shares. Chardan Capital started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set a "buy" rating and a $30.00 price target on the stock. Needham & Company LLC started coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They set a "buy" rating and a $35.00 price target on the stock. Guggenheim reiterated a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley reiterated an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd.

Insider Transactions at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 2,080 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $14.01, for a total transaction of $29,140.80. Following the completion of the sale, the general counsel now owns 105,386 shares of the company's stock, valued at $1,476,457.86. This represents a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Arjun Goyal bought 44,939 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were purchased at an average cost of $12.24 per share, with a total value of $550,053.36. Following the transaction, the director now directly owns 44,939 shares of the company's stock, valued at $550,053.36. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders sold 162,398 shares of company stock valued at $2,109,252. Company insiders own 7.09% of the company's stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTA. Janus Henderson Group PLC lifted its position in Centessa Pharmaceuticals by 279.2% during the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock valued at $82,218,000 after acquiring an additional 3,614,623 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Centessa Pharmaceuticals by 35.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company's stock valued at $99,999,000 after acquiring an additional 1,834,973 shares during the last quarter. Foresite Capital Management VI LLC acquired a new position in Centessa Pharmaceuticals during the 4th quarter valued at approximately $20,994,000. Point72 Asset Management L.P. increased its stake in Centessa Pharmaceuticals by 26.2% during the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock valued at $57,396,000 after purchasing an additional 710,936 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Centessa Pharmaceuticals by 14.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock valued at $89,854,000 after purchasing an additional 685,371 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Price Performance

Shares of CNTA opened at $12.43 on Friday. The company has a market capitalization of $1.66 billion, a P/E ratio of -6.87 and a beta of 1.48. The company has a quick ratio of 14.37, a current ratio of 14.37 and a debt-to-equity ratio of 0.28. The firm has a 50 day moving average of $12.70 and a 200 day moving average of $14.87. Centessa Pharmaceuticals has a twelve month low of $8.46 and a twelve month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.15. As a group, equities research analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.